Article info

Download PDFPDF

Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride

Authors

  • Hong Liang Sorbonne Universités, INSERM, CNRS, Institut de la Vision, Paris, France PubMed articlesGoogle scholar articles
  • Antoine Labbé Sorbonne Universités, INSERM, CNRS, Institut de la Vision, Paris, France CHNO des Quinze-Vingts, IHU FOReSIGHT, INSERM-DGOS CIC 1423, Paris, France Department of Ophthalmology, Hôpital Ambroise Paré, AP-HP, Université Versailles St Quentin en Yvelines, Montigny-Le-Bretonneux, 78180, France PubMed articlesGoogle scholar articles
  • Christophe Baudouin Sorbonne Universités, INSERM, CNRS, Institut de la Vision, Paris, France CHNO des Quinze-Vingts, IHU FOReSIGHT, INSERM-DGOS CIC 1423, Paris, France Department of Ophthalmology, Hôpital Ambroise Paré, AP-HP, Université Versailles St Quentin en Yvelines, Montigny-Le-Bretonneux, 78180, France PubMed articlesGoogle scholar articles
  • Celine Plisson Recordati Rare Diseases, Puteaux, Puteaux, France PubMed articlesGoogle scholar articles
  • Vincenzo Giordano Recordati Rare Diseases, Puteaux, Puteaux, France PubMed articlesGoogle scholar articles
  1. Correspondence to DrHong Liang, Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, 28, Rue De Charenton, 75012 Paris, France; lianghongfr{at}yahoo.fr
View Full Text

Citation

Liang H, Labbé A, Baudouin C, et al
Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride

Publication history

  • Received April 1, 2020
  • Revised May 5, 2020
  • First published June 27, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.